1. Academic Validation
  2. DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model

DRD1 agonist A-68930 improves mitochondrial dysfunction and cognitive deficits in a streptozotocin-induced mouse model

  • Brain Res Bull. 2021 Oct;175:136-149. doi: 10.1016/j.brainresbull.2021.07.015.
Zhao-Yan Cheng 1 Yu-Hui Hu 1 Qing-Peng Xia 1 Chen Wang 1 Ling He 2
Affiliations

Affiliations

  • 1 Department of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China.
  • 2 Department of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: heling92@hotmail.com.
Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder characterized by irreversible cognitive deficits and memory dysfunction. Dopamine is the most abundant catecholaminergic neurotransmitter in the brain which regulates motivation, reward, movement, and cognition. Recently, increasing evidences have shown that dopaminergic system is disturbed in AD conditions, and pharmacological interventions targeting dopamine D1 receptor (DRD1) exhibit certain therapeutic benefits in AD models. However, the underlying link between DRD1 and AD remains elusive. This study sought to test whether the selective DRD1 agonist A-68930 could improve streptozotocin (STZ)-induced cognitive impairment in mice. Here we found that A-68930 treatment through intraperitoneal injection efficiently alleviated STZ-induced cognitive deficits in mice. Moreover, our mechanism researches revealed that the DRD1 signaling induced by A-68930 significantly rescued STZ-induced mitochondrial biogenesis deficit, mitochondrial dysfunction, Aβ overexpression, and tau phosphorylation in mice hippocampus and cortex and SH-SY5Y cells, which may be mediated through stimulating AMPK/PGC-1α pathway. This study indicates that DRD1 agonist A-68930 can improve STZ-induced cognitive deficits and mitochondrial dysfunction in vivo and in vitro, and DRD1 may represent an appropriate target candidate for AD drug development.

Keywords

Alzheimer’s disease; Dopamine D1 receptor; Mitochondrial biogenesis; Mitochondrial dysfunction; PGC-1α.

Figures
Products